Abstract 3328
Background
SHR-1210 is a humanized anti–PD-1 antibody, with immunoglobulin gamma 4 (IgG4) as heavy chain and immunoglobulin kappa (IgK) as light chain expressed in the supernatant of a Chinese hamster ovary (CHO) stable cell line. Antitumor activity data for the ongoing clinical studies of SHR-1210 are currently being evaluated. SHR-1210 is currently being tested in 15 studies in advanced malignancies: 4 in advanced solid tumors, 3 in NSCLC, 2 in hepatocellular cancer (HCC; including 1 in HCC or gastric cancer [GC]), 2 in esophageal cancer (EC), 1 in melanoma, 1 in nasopharyngeal cancer (NPC), 1 in primary liver cancer (PLC), and 1 in classic Hodgkin lymphoma (cHL). Since 22 MAY 2017, 395 patients have been enrolled in this trial.
Trial design
In this trial, 412 patients will be randomly assigned in a 1:1 ratio, to receive either carboplatin-pemetrexed chemotherapy,OR receive SHR-1210 combined with carboplatin-pemetrexed chemotherapy. Randomization will be stratified according to gender and smoking history. All the patients will receive carboplatin(area under the curve 5) plus pemetrexed(500 mg/m2), all administered as IV infusion on Day 1 of each 3-week cycle for 4 or 6 cycles of the investigator's choice, followed by pemetrexed(500 mg/m2) every 3 weeks(Q3W) maintenance for the remainder of the study. Patients assigned to the SHR-1210 combined with chemotherapy arm, will additionally receive SHR-1210(200mg) administered as IV infusion on Day 1 of each 3-week cycle, for up to 35 cycles. Patients assigned to the chemotherapy arm will have the opportunity to crossover to receive SHR-1210(200mg) monotherapy every 3 weeks(Q3W) once they experience progression of disease (PD) defined by RECIST 1.1 and meet all crossover criteria.
Clinical trial identification
NCT03134872.
Legal entity responsible for the study
Jiangsu HengRui Medicine Co., Ltd.
Funding
Jiangsu HengRui Medicine Co., Ltd.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4679 - Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase 2 trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma
Presenter: Chung-Han Lee
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5379 - End-to-end learning to predict survival in patients with gastric cancer using convolutional neural networks
Presenter: Armin Meier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5394 - Detection of Targetable Kinase Fusions in 7260 patients in an integrated Cancer System
Presenter: Ankur Parikh
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5884 - Clinical and analytical validation of an FDA approved comprehensive genomic profiling (CGP) assay incorporating multiple companion diagnostics for targeted and immunotherapies
Presenter: Yali Li
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5912 - SET overexpression promotes colorectal cancer progression and determines poor outcome in patients with localized disease.
Presenter: Blanca Torrejón
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1168 - The functional MDM4 genetic variant in advanced lung adenocarcinoma patients treated with EGFR-TKIs
Presenter: Nasha Zhang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3071 - PD-L1 expression on pre-treatment circulating tumour cells, but not serum VEGF, is predictive of response to pembrolizumab in melanoma
Presenter: Muhammad Khattak
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4062 - Olaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer
Presenter: Yu-Zhen Liu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4801 - A diagnostic model for hepatitis B virus-related hepatocellular carcinoma in China: a large-scale, multi-center study
Presenter: Tian Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4874 - Dissecting Gastric Cancer biology and how and when to use immunotherapy
Presenter: Meghna Das Thakur
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract